Imsidolimab

Name: Imsidolimab in Generalized pustular psoriasis: Pathophysiology
Published: 2026-09-14T15:39:06-04:00

Generalized pustular psoriasis

Manufacturer: Vanda Pharmaceuticals
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Pathophysiology

1 evidence topic · 2 sources

Pathophysiology

“Aberrant interleukin-36Ra structure and function lead to unregulated secretion of inflammatory cytokines and generalized pustular psoriasis.” (opens the source at this quote in a new tab)